PDF herunterladen
CC BY 4.0 · J Neuroanaesth Crit Care
DOI: 10.1055/s-0044-1782509
Review Article

Critical Care in Guillain–Barré Syndrome

G S Umamaheswara Rao
1   Department of Neuroanaesthesia and Neurocritical Care, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Guillain–Barré syndrome (GBS) is an autoimmune polyneuropathy characterized by hyporeflexic neuromuscular paralysis and albuminocytologic dissociation in the cerebrospinal fluid. It is a postinfectious disorder. The most common antecedent illnesses are respiratory tract infection and Campylobacter jejuni infection. After the antecedent infection, specific antibodies are generated that cross-react with gangliosides in the host culminating in demyelination of the peripheral nerves or nerve roots. Complement activation also contributes to nerve degeneration. Bilateral symmetrical progression of the limb weakness occurs over a period of a few days followed by a plateau phase, after which a recovery phase follows. Generalized hypotonia and hyporeflexia characterize the limb weakness. Cerebrospinal fluid analysis shows albuminocytologic dissociation. About one-third of patients develop respiratory failure. Neuropathic pain is a disturbing symptom in GBS. Dysautonomia is very characteristic of GBS. Erasmus GBS respiratory insufficiency score predicts the need for mechanical ventilation. The weaning process from mechanical ventilation mainly depends on the recovery of vital capacity and inspiratory force. The definitive treatment for GBS consists of plasma exchange or intravenous immunoglobulin therapy both of which are equally efficacious. Seasonal variation has been observed in the occurrence and recovery of GBS. Prognosis of GBS varies widely. Erasmus GBS outcome scale scoring system predicts the ability of the patient to walk independently after 6 months. Several GBS cases have been reported globally during recent pandemic of coronavirus disease 2019. Though GBS is a self-limiting disease, there are quite a few research questions that still remain to be answered.

Keywords

autoimmune disease - critical care - GBS - neuromuscular disease - ventilation


Publikationsverlauf

Artikel online veröffentlicht:
02. Mai 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculonévrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire: remarques sur les caractères cliniques et graphiques des réflexes tendineux. Bulletins et mémoires de la Société des Médecins des Hôpitaux de Paris 1916; 40: 1462-1470
    PubMedGoogle Scholar
  • 2 Afifi AK. The Landry-Guillain-Barré Strohl syndrome 1859 to 1992 a historical perspective. J Family Community Med 1994; 1 (01) 30-34
    CrossrefPubMedGoogle Scholar
  • 3 Goodfellow JA, Willison HJ. Guillain-Barré syndrome: a century of progress. Nat Rev Neurol 2016; 12 (12) 723-731
    CrossrefPubMedGoogle Scholar
  • 4 Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36 (02) 123-133
    CrossrefPubMedGoogle Scholar
  • 5 Auger N, Quach C, Healy-Profitós J, Dinh T, Chassé M. Early predictors of Guillain-Barré syndrome in the life course of women. Int J Epidemiol 2018; 47 (01) 280-288
    CrossrefPubMedGoogle Scholar
  • 6 Doets AY, Verboon C, van den Berg B. et al; IGOS Consortium. Regional variation of Guillain-Barré syndrome. Brain 2018; 141 (10) 2866-2877
    CrossrefPubMedGoogle Scholar
  • 7 McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009; 32 (02) 150-163
    CrossrefPubMedGoogle Scholar
  • 8 Jacobs BC, Rothbarth PH, van der Meché FG. et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998; 51 (04) 1110-1115
    CrossrefPubMedGoogle Scholar
  • 9 van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG treatment and prognosis in Guillain-Barré syndrome. J Clin Immunol 2010; 30 (Suppl 1, Suppl 1): S74-S78
    CrossrefPubMedGoogle Scholar
  • 10 Tam CC, Rodrigues LC, Petersen I, Islam A, Hayward A, O'Brien SJ. Incidence of Guillain-Barré syndrome among patients with Campylobacter infection: a general practice research database study. J Infect Dis 2006; 194 (01) 95-97
    CrossrefPubMedGoogle Scholar
  • 11 Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol 2013; 12 (12) 1180-1188
    CrossrefPubMedGoogle Scholar
  • 12 Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002; 125 (Pt 12): 2591-2625
    CrossrefPubMedGoogle Scholar
  • 13 Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000; 48 (04) 624-631
    CrossrefPubMedGoogle Scholar
  • 14 Visser LH, Van der Meché FG, Van Doorn PA. et al; Dutch Guillain-Barré Study Group. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Brain 1995; 118 (Pt 4): 841-847
    CrossrefPubMedGoogle Scholar
  • 15 Yuki N, Ho TW, Tagawa Y. et al. Autoantibodies to GM1b and GalNAc-GD1a: relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China. J Neurol Sci 1999; 164 (02) 134-138
    CrossrefPubMedGoogle Scholar
  • 16 Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992; 31 (06) 677-679
    CrossrefPubMedGoogle Scholar
  • 17 Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome). J Neuroimmunol 2009; 215 (1-2): 1-9
    CrossrefPubMedGoogle Scholar
  • 18 Hafer-Macko C, Hsieh ST, Li CY. et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996; 40 (04) 635-644
    CrossrefPubMedGoogle Scholar
  • 19 McGonigal R, Rowan EG, Greenshields KN. et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 2010; 133 (Pt 7): 1944-1960
    CrossrefPubMedGoogle Scholar
  • 20 Susuki K, Rasband MN, Tohyama K. et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007; 27 (15) 3956-3967
    CrossrefPubMedGoogle Scholar
  • 21 Kuitwaard K, van Koningsveld R, Ruts L, Jacobs BC, van Doorn PA. Recurrent Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2009; 80 (01) 56-59
    CrossrefPubMedGoogle Scholar
  • 22 Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ. et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol 1979; 110 (02) 105-123
    CrossrefPubMedGoogle Scholar
  • 23 Salmon DA, Proschan M, Forshee R. et al; H1N1 GBS Meta-Analysis Working Group. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet 2013; 381 (9876) 1461-1468
    CrossrefPubMedGoogle Scholar
  • 24 van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014; 10 (08) 469-482
    CrossrefPubMedGoogle Scholar
  • 25 Inloo S, Katibeh P. Guillain-Barre syndrome presenting with bilateral facial nerve palsy. Iran J Child Neurol 2014; 8: 70-72 PubMed
    PubMedGoogle Scholar
  • 26 Azarisman SMS, Shahrin TCA, Marzuki AO, Fatnoon NNA, Rathor MY. Bilateral facial nerve palsy secondary to an atypical presentation of Guillain-Barré syndrome. IMJ 2009; 8: 41-44
    PubMedGoogle Scholar
  • 27 Burakgazi AZ, Höke A. Respiratory muscle weakness in peripheral neuropathies. J Peripher Nerv Syst 2010; 15 (04) 307-313
    CrossrefPubMedGoogle Scholar
  • 28 Hughes RA, Wijdicks EF, Benson E. et al; Multidisciplinary Consensus Group. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005; 62 (08) 1194-1198
    CrossrefPubMedGoogle Scholar
  • 29 Bazán-Rodríguez L, Ruiz-Avalos JA, de Saráchaga AJ, Martinez-Jimenez E, López-Hernández JC, Vargas-Cañas S. Dysautonomia and related outcomes in Guillain-Barre syndrome. Auton Neurosci 2023; 245: 103070
    CrossrefPubMedGoogle Scholar
  • 30 Chakraborty T, Kramer CL, Wijdicks EFM, Rabinstein AA. Dysautonomia in Guillain-Barré syndrome: prevalence, clinical spectrum, and outcomes. Neurocrit Care 2020; 32 (01) 113-120
    CrossrefPubMedGoogle Scholar
  • 31 Tan CY, Shahrizaila N, Tan HT, Goh KJ, Tan MP. Cardiovascular autonomic assessment in Guillain-Barré syndrome: a longitudinal study. Neurol India 2022; 70 (05) 1856-1859
    CrossrefPubMedGoogle Scholar
  • 32 Song X, Chi C, Song J, Zhu J. Isolated right ventricular Takotsubo cardiomyopathy in Guillain-Barré syndrome. BMC Cardiovasc Disord 2022; 22 (01) 531
    CrossrefPubMedGoogle Scholar
  • 33 Peña L, Moreno CB, Gutierrez-Alvarez AM. Pain management in Guillain-Barre syndrome: a systematic review. Neurología 2015; 30 (07) 433-438
    PubMedGoogle Scholar
  • 34 Kuroda H, Fujihara K, Nakashima I. et al. Pregabalin attenuates dysautonomia as well as painful dysesthesia caused by Guillain–Barré syndrome. Clin Exp Neuroimmunol 2013; 4: 75-78
    CrossrefPubMedGoogle Scholar
  • 35 Sharshar T, Chevret S, Bourdain F, Raphaël JC. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med 2003; 31 (01) 278-283
    CrossrefPubMedGoogle Scholar
  • 36 Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001; 58 (06) 893-898
    CrossrefPubMedGoogle Scholar
  • 37 Paul BS, Bhatia R, Prasad K, Padma MV, Tripathi M, Singh MB. Clinical predictors of mechanical ventilation in Guillain-Barré syndrome. Neurol India 2012; 60 (02) 150-153
    CrossrefPubMedGoogle Scholar
  • 38 Doets AY, Walgaard C, Lingsma HF. et al; IGOS Consortium. International validation of the Erasmus Guillain-Barré syndrome respiratory insufficiency score. Ann Neurol 2022; 91 (04) 521-531
    CrossrefPubMedGoogle Scholar
  • 39 Vianello A, Bevilacqua M, Arcaro G, Gallan F, Serra E. Non-invasive ventilatory approach to treatment of acute respiratory failure in neuromuscular disorders. A comparison with endotracheal intubation. Intensive Care Med 2000; 26 (04) 384-390
    CrossrefPubMedGoogle Scholar
  • 40 Plummer AL, Gracey DR. Consensus conference on artificial airways in patients receiving mechanical ventilation. Chest 1989; 96 (01) 178-180
    CrossrefPubMedGoogle Scholar
  • 41 Lawn ND, Wijdicks EF. Post-intubation pulmonary function test in Guillain-Barré syndrome. Muscle Nerve 2000; 23 (04) 613-616
    CrossrefPubMedGoogle Scholar
  • 42 Shang P, Zhu M, Baker M, Feng J, Zhou C, Zhang HL. Mechanical ventilation in Guillain-Barré syndrome. Expert Rev Clin Immunol 2020; 16 (11) 1053-1064
    CrossrefPubMedGoogle Scholar
  • 43 The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology 1985; 35 (08) 1096-1104
    CrossrefPubMedGoogle Scholar
  • 44 Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2017; 2 (02) CD001798
    PubMedGoogle Scholar
  • 45 Bauer PR, Ostermann M, Russell L. et al; Nine-I Investigators. Plasma exchange in the intensive care unit: a narrative review. Intensive Care Med 2022; 48 (10) 1382-1396
    CrossrefPubMedGoogle Scholar
  • 46 Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008; 52 (06) 1180-1196
    CrossrefPubMedGoogle Scholar
  • 47 Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349 (9047) 225-230
    CrossrefPubMedGoogle Scholar
  • 48 van der Meché FGA, Schmitz PIM. Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326 (17) 1123-1129
    CrossrefPubMedGoogle Scholar
  • 49 Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet 1997; 350 (9093) 1747
    CrossrefPubMedGoogle Scholar
  • 50 Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29 (03) 173-184
    CrossrefPubMedGoogle Scholar
  • 51 Arumugham VB, Rayi A. Intravenous Immunoglobulin (IVIG). In: StatPearls [Internet]. Treasure Island (FL):: StatPearls Publishing;; 2023. Jan
    Google Scholar
  • 52 Bondi M, Engel-Haber E, Wolff J, Grosman-Rimon L, Bloch A, Zeilig G. Functional outcomes following inpatient rehabilitation of Guillain-Barré syndrome patients: intravenous immunoglobulins versus plasma exchange. NeuroRehabilitation 2021; 48 (04) 543-551
    CrossrefPubMedGoogle Scholar
  • 53 Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014; 2014 (09) CD002063
    PubMedGoogle Scholar
  • 54 Verboon C, van den Berg B, Cornblath DR. et al; IGOS Consortium. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. J Neurol Neurosurg Psychiatry 2020; 91 (02) 113-121
    CrossrefPubMedGoogle Scholar
  • 55 Netto AB, Kulkarni GB, Taly AB, Rao GU, Periyavan S, Rao S. A comparison of immunomodulation therapies in mechanically ventilated patients with Guillain Barré syndrome. J Clin Neurosci 2012; 19 (12) 1664-1667
    CrossrefPubMedGoogle Scholar
  • 56 Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2016; 10 (10) CD001446
    CrossrefPubMedGoogle Scholar
  • 57 Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012; 366 (24) 2294-2304
    CrossrefPubMedGoogle Scholar
  • 58 Halstead SK, Zitman FM, Humphreys PD. et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008; 131 (Pt 5): 1197-1208
    CrossrefPubMedGoogle Scholar
  • 59 Pineda AA, Minohara M, Kawamura N. et al. Preventive and therapeutic effects of the selective Rho-kinase inhibitor Fasudil on experimental autoimmune neuritis. J Neurol Sci 2011; 306 (1-2): 115-120
    CrossrefPubMedGoogle Scholar
  • 60 Zhang G, Lehmann HC, Bogdanova N, Gao T, Zhang J, Sheikh KA. Erythropoietin enhances nerve repair in anti-ganglioside antibody-mediated models of immune neuropathy. PLoS One 2011; 6 (10) e27067
    CrossrefPubMedGoogle Scholar
  • 61 Webb AJ, Brain SA, Wood R, Rinaldi S, Turner MR. Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry 2015; 86 (11) 1196-1201
    CrossrefPubMedGoogle Scholar
  • 62 Sriganesh K, Netto A, Kulkarni GB, Taly AB, Umamaheswara Rao GS. Seasonal variation in the clinical recovery of patients with Guillain Barré syndrome requiring mechanical ventilation. Neurol India 2013; 61 (04) 349-354
    CrossrefPubMedGoogle Scholar
  • 63 Korinthenberg R, Trollmann R, Felderhoff-Müser U. et al. Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: an evidence- and consensus-based guideline. Eur J Paediatr Neurol 2020; 25: 5-16
    CrossrefPubMedGoogle Scholar
  • 64 Nagappa M, Rahul W, Sinha S. et al. Guillain Barre Syndrome in the elderly: experience from a tertiary-care hospital in India. J Clin Neurosci 2017; 46: 45-49
    CrossrefPubMedGoogle Scholar
  • 65 López-Hernández JC, Briseño-Godinez ME, Pérez-Valdez EY. et al. Inpatient delirium in Guillain-Barré syndrome: frequency and clinical characteristics in a Mexican hospital. Cureus 2021; 13 (11) e19260
    PubMedGoogle Scholar
  • 66 Durand MC, Porcher R, Orlikowski D. et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. Lancet Neurol 2006; 5 (12) 1021-1028
    CrossrefPubMedGoogle Scholar
  • 67 van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007; 6 (07) 589-594
    CrossrefPubMedGoogle Scholar
  • 68 Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 2011; 76 (11) 968-975
    CrossrefPubMedGoogle Scholar
  • 69 Agarwal E, Bhagat A, Srivastava K. et al. Clinical and electrophysiological factors predicting prolonged recovery in children with Guillain-Barré syndrome. Indian J Pediatr 2022; 89 (05) 452-458
    CrossrefPubMedGoogle Scholar
  • 70 Netto AB, Taly AB, Kulkarni GB, Rao UG, Rao S. Mortality in mechanically ventilated patients of Guillain Barré syndrome. Ann Indian Acad Neurol 2011; 14 (04) 262-266
    CrossrefPubMedGoogle Scholar
  • 71 Nagappa M, Netto AB, Taly AB. et al. Electrophysiological observations in critically ill Guillain-Barre syndrome. Neurol India 2016; 64 (05) 914-920
    CrossrefPubMedGoogle Scholar
  • 72 Dhamne MC, Benny R, Singh R. et al. Guillian–Barre' syndrome in patients with SARS-CoV-2: a multicentric study from Maharashtra, India. Ann Indian Acad Neurol 2021; 24 (03) 339-346
    CrossrefPubMedGoogle Scholar
  • 73 Bentley SA, Ahmad S, Kobeissy FH, Toklu HZ. Concomitant Guillain-Barré syndrome and COVID-19: a meta-analysis of cases. Medicina (Kaunas) 2022; 58 (12) 1835
    CrossrefPubMedGoogle Scholar
  • 74 Abolmaali M, Rezania F, Behnagh AK, Hamidabad NM, Gorji A, Mirzaasgari Z. Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review. Immunol Res 2022; 70 (06) 752-764
    CrossrefPubMedGoogle Scholar
  • 75 Chan LY, Tsui MH, Leung TN. Guillain-Barré syndrome in pregnancy. Acta Obstet Gynecol Scand 2004; 83 (04) 319-325
    PubMedGoogle Scholar
  • 76 Feldman JM. Cardiac arrest after succinylcholine administration in a pregnant patient recovered from Guillain-Barré syndrome. Anesthesiology 1990; 72 (05) 942-944
    CrossrefPubMedGoogle Scholar
  • 77 Papri N, Doets AY, Mohammad QD. et al Validation and adjustment of modified Erasmus GBS outcome score in Bangladesh. Ann Clin Transl Neurol 2022; 9 (08) 1264-1275
    CrossrefPubMedGoogle Scholar